Ozempic Off-Label Use: What the Science Says

Introduction

Ozempic (semaglutide 0.5–2 mg weekly injection) was FDA-approved in 2017 for type 2 diabetes management. Yet prescriptions have expanded far beyond that original indication. In Denmark, the share of new semaglutide users without type 2 diabetes grew from just 1% in 2018 to 33% by 2022 — a 33-fold increase in off-label prescribing in under four years.

Evidence: "The proportion of new users without type 2 diabetes increased from 1% in 2018 to 33% in 2022." — Falster MO, et al. Pharmacoepidemiol Drug Saf. 2024. PubMed

That trend reflects a cascade of landmark clinical trials showing that semaglutide's benefits extend well beyond blood sugar control. Researchers have investigated its role in cardiovascular protection, chronic kidney disease, liver disease, polycystic ovary syndrome (PCOS), and even alcohol use disorder.

This article reviews the peer-reviewed evidence for each off-label application, distinguishing approved indications from emerging ones and helping patients and clinicians understand what the data actually supports.

What "Off-Label" Means — and Why It Matters

Off-label prescribing is legal and common in the United States. The FDA approves drugs for specific indications based on submitted trial data, but physicians may prescribe any approved medication for any medical purpose they judge to be clinically appropriate.

Ozempic's current FDA-approved indications are:

Type 2 diabetes (glycemic control) — approved 2017
Reducing cardiovascular events in adults with T2D and established cardiovascular disease — approved 2020

Wegovy (semaglutide 2.4 mg weekly) holds separate FDA approval for chronic weight management. When physicians prescribe Ozempic's formulation for weight loss alone, that is off-label use.

The distinction matters for insurance coverage and regulatory oversight, but it does not inherently make a use unsafe or unproven. Several off-label applications of semaglutide are now backed by phase 2 and phase 3 randomized controlled trials.

Cardiovascular Protection in Non-Diabetic Patients

The SELECT trial — one of the largest GLP-1 receptor agonist trials ever conducted — enrolled 17,604 adults with obesity or overweight and pre-existing cardiovascular disease but without diabetes. Participants received semaglutide 2.4 mg weekly or placebo for a median of 34 months.

Evidence: "Semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with pre-existing cardiovascular disease who did not have diabetes." — Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563

The primary endpoint — a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke — was reduced by 20% in the semaglutide group. This finding is clinically significant because it shows semaglutide's cardiovascular benefit is independent of its glucose-lowering effect.

What This Means for Off-Label Prescribing

Cardiologists and internists increasingly consider semaglutide for patients with established heart disease and obesity even in the absence of diabetes. The SELECT trial data provides robust phase 3 evidence supporting this approach, though the formulation used (2.4 mg Wegovy) differs from Ozempic's standard dosing.

Chronic Kidney Disease: The FLOW Trial

Diabetic kidney disease is the leading cause of end-stage renal disease worldwide. The FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease (CKD stages 2–4) and randomized them to semaglutide 1 mg weekly or placebo.

Evidence: "The risk of a primary-outcome event — a composite of major kidney disease events or cardiovascular or renal death — was 24% lower in the semaglutide group than in the placebo group." — Perkovic V, et al. N Engl J Med. 2024;391(2):109-121. DOI: 10.1056/NEJMoa2403347

The trial was stopped early due to the strength of benefit. The primary outcome reduction of 24% was driven by slower eGFR decline, reduced kidney failure events, and fewer cardiovascular deaths. The FDA has since reviewed this data in the context of a potential kidney-specific indication.

Beyond diabetic CKD, a 24-week randomized trial found that semaglutide also reduced urinary albumin-to-creatinine ratio (UACR) by 52.1% in patients with overweight or obesity and non-diabetic CKD compared to placebo — suggesting the renal benefits may not require diabetes at baseline.

Evidence: "Treatment with semaglutide vs placebo reduced UACR by -52.1% in patients with overweight/obesity and non-diabetic CKD." — Górriz JL, et al. Kidney Int. 2024. PubMed

Metabolic Liver Disease (MASH)

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, affects an estimated 6–8% of US adults and lacks many treatment options. The ESSENCE phase 3 trial evaluated semaglutide 2.4 mg weekly in patients with MASH and moderate-to-advanced fibrosis (F2–F3).

Interim results demonstrated that 72 weeks of semaglutide treatment achieved both primary histological endpoints — MASH resolution without fibrosis worsening, and fibrosis improvement without MASH worsening — at rates significantly superior to placebo. Based on these results, the FDA granted Wegovy accelerated approval for MASH with F2–F3 fibrosis in August 2025.

The 2025 AASLD (American Association for the Study of Liver Diseases) Practice Guidance update incorporated semaglutide as a therapeutic option for this indication, reflecting the rapid translation of trial data into clinical guidelines.

Evidence: "Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance." — Rinella ME, et al. Hepatology. 2025. PubMed

While this indication has now received accelerated FDA approval for the Wegovy formulation, Ozempic's lower-dose formulation is sometimes prescribed off-label for MASH patients who cannot access Wegovy.

Polycystic Ovary Syndrome (PCOS)

PCOS affects 6–12% of reproductive-age women and is characterized by insulin resistance, androgen excess, and irregular menstruation. GLP-1 receptor agonists are not FDA-approved for PCOS, but evidence is building.

A 2024 meta-analysis of randomized controlled trials examined GLP-1 receptor agonists in women with PCOS and obesity. The analysis found that GLP-1 RAs were associated with significant reductions in BMI, waist circumference, serum triglycerides, and total testosterone compared to placebo or active comparators.

Evidence: "GLP-1 RA use was associated with significant reduction in waist circumference, BMI, serum triglycerides, and total testosterone levels in PCOS women living with obesity." — Khalid MF, et al. Obes Rev. 2024. PubMed

A prospective RCT published in 2025 found that combination semaglutide (1 mg weekly) plus metformin significantly improved menstrual regularity, reduced androgen levels, improved insulin sensitivity, and increased natural pregnancy rates compared to metformin alone in 100 overweight women with PCOS over 16 weeks.

Evidence: "Combination semaglutide plus metformin significantly reduced body weight, improved insulin resistance, decreased inflammatory markers, alleviated menstrual irregularities, and increased natural pregnancy rates in PCOS." — Zhang Y, et al. Front Endocrinol. 2025. PubMed

Clinical Implications

Reproductive endocrinologists often weigh semaglutide for PCOS patients who have failed lifestyle modification and metformin, particularly when weight loss is a goal. Phase 3 trials specifically powered for PCOS outcomes are ongoing, and FDA approval for this indication may follow if results are positive.

Alcohol Use Disorder

Perhaps the most surprising off-label frontier is addiction medicine. Preclinical data suggested GLP-1 receptors in the brain's reward circuitry modulate dopamine signaling — the same pathway involved in substance use.

A phase 2, double-blind, randomized clinical trial published in JAMA Psychiatry in February 2025 enrolled 48 non-treatment-seeking adults with alcohol use disorder and randomized them to once-weekly semaglutide (titrating from 0.25 to 1.0 mg) or placebo over 9 weeks.

Evidence: "Semaglutide led to significantly reduced weekly alcohol craving relative to placebo (β = -0.39; 95% CI, -0.73 to -0.06; p = .01) and reductions in some measures of weekly consumption." — Hendershot CS, et al. JAMA Psychiatry. 2025. PubMed

While craving reduction was statistically significant, not all measures of alcohol consumption reached significance in this small trial. A larger phase 3 study (NCT05895643) is ongoing to determine whether these effects are robust enough to support a formal indication.

Off-Label Use Trends and Prescribing Patterns

The Ozempic shortage of 2022–2023 brought off-label prescribing into the spotlight. Population-level data from Denmark quantified the shift: among all new semaglutide initiators by the end of 2022, one in three did not have type 2 diabetes. The primary off-label driver was weight management — which has since gained its own formal approval via Wegovy.

Summary Table: Semaglutide Off-Label Applications

Indication	Evidence Level	Semaglutide Dose	FDA Status
Cardiovascular prevention (no T2D)	Phase 3 RCT (SELECT)	2.4 mg/wk	Wegovy approved
Chronic kidney disease (T2D)	Phase 3 RCT (FLOW)	1.0 mg/wk	Ozempic label updated
Non-diabetic CKD	Phase 2 RCT	1.0 mg/wk	Off-label
MASH (F2–F3 fibrosis)	Phase 3 RCT (ESSENCE)	2.4 mg/wk	Wegovy accelerated approval (Aug 2025)
PCOS	Meta-analysis + RCTs	0.5–1.0 mg/wk	Off-label
Alcohol use disorder	Phase 2 RCT	0.25–1.0 mg/wk	Off-label

Key Takeaways

Semaglutide's mechanism — activating GLP-1 receptors in the pancreas, brain, heart, and kidneys — creates a broad therapeutic profile that extends well beyond glucose control. The strongest off-label evidence supports:

Cardiovascular protection in non-diabetic obese patients (SELECT trial; 20% MACE reduction)
Renal protection in diabetic and non-diabetic CKD (FLOW trial; 24% composite reduction)
Liver disease in MASH — now formally approved for Wegovy formulation
PCOS management through weight loss, androgen reduction, and improved metabolic parameters
Alcohol use disorder — promising early data, phase 3 trials ongoing

Patients should not initiate semaglutide for any off-label purpose without a physician's evaluation. Insurance coverage for off-label use is variable and often requires prior authorization. For those interested in how semaglutide compares with other GLP-1 agents, see our guide to Wegovy vs Ozempic and the semaglutide dosage guide.

References

Falster MO, et al. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 — User Trends and Off-Label Prescribing for Weight Loss. Pharmacoepidemiol Drug Saf. 2024. PubMed
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. DOI: 10.1056/NEJMoa2403347
Górriz JL, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Kidney Int. 2024. PubMed
Rinella ME, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025. PubMed
Khalid MF, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. Obes Rev. 2024. PubMed
Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PubMed

Last updated: 2026-03-09 Medical review: Dr. James Chen, MD, PhD, FACE